As the global demand for RNA-based therapeutics and vaccines accelerates, traditional plasmid DNA (pDNA) production methods often struggle to meet today’s biopharmaceutical landscape’s scalability and efficiency requirements. Touchlight’s z- dbDNA technology delivers a groundbreaking alternative, enabling rapid, high-quality RNA manufacturing with unmatched purity and scalability.

This article explores how Touchlight’s z- dbDNA transforms RNA vaccine and therapeutic development, offering a cost-effective, efficient solution to empower innovation across mRNA, self-amplifying RNA (saRNA), and more.

What You’ll Learn:

• How Touchlight’s z- dbDNA overcomes challenges in RNA manufacturing
• The benefits of synthetic DNA for RNA-based therapeutics
• Why Touchlight’s z- dbDNA is ideal for scalable mRNA and saRNA production